NCT04922021 - An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

June 2, 2022

Study Completion Date

September 26, 2022

Conditions

Atopic Dermatitis

Interventions

DRUG

LEO 138559

LEO 138559 is an antibody given by injection just under the skin.

DRUG

LEO 138559 placebo

LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.

Trial Locations (17)

10117

LEO Pharma Investigational Site, Berlin

23538

LEO Pharma Investigational Site, Lübeck

33012

LEO Pharma Investigational Site, Hialeah

33122

LEO Pharma Investigational Site, Doral

35209

LEO Pharma Investigational Site, Birmingham

90045

LEO Pharma Investigational Site, Los Angeles

92708

LEO Pharma Investigational Site, Fountain Valley

L3P 1X3

LEO Pharma Investigational Site, Markham

L5H 1G9

LEO Pharma Investigational Site, Mississauga

K9J 5K2

LEO Pharma Investigational Site, Peterborough

01307

LEO Pharma Investigational Site, Dresden

04103

LEO Pharma Investigational Site, Leipzig

30-033

LEO Pharma Investigational Site, Krakow

31-011

LEO Pharma Investigational Site, Krakow

35-055

LEO Pharma nvestigational Site, Rzeszów

02-625

LEO Pharma Investigational Site, Warsaw

51-685

LEO Pharma Investigational Site, Wroclaw